viewIncanthera Ltd

Incanthera believe new skin cancer prevention cream reveals 'all positives and no negatives'

Incanthera PLC's (AQSE:INC) CEO Simon Ward and Kevin Hammond talk to Proactive London's Katie Pilbeam about new positive data from new skin permeation and sensitisation studies of its Sol skin cancer technology.

Both Simon and Kevin explain that Sol is a cream designed to deliver an active agent into the skin that is known to prevent the formation of solar (actinic) keratosis and skin cancer.

The results reveal that Sol is 'non-irritant' and comparable to baby sun protection products tested previously. They discuss the route to commercialism and hint at 'exciting conversations' happening behind closed doors.

Quick facts: Incanthera Ltd

Price: 17 GBX

Market: AQSE
Market Cap: -

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Incanthera Ltd named herein, including the promotion by the Company of Incanthera Ltd in any Content on the Site, the Company receives from...


Incanthera says it's making great progress towards commercialisation of lead...

Incanthera's (LON:INC) Simon Ward and Tim McCarthy speak to Proactive following the release of its first set of results since listing earlier this year on the AQSE Growth Market. CEO ward describes it as a pivotal year for the company and says they're now fully focused on further development...

on 15/6/20

2 min read